PET imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented this week at the 2009 American Society of Radiation Oncology meeting.
PET imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented this week at the 2009 American Society of Radiation Oncology meeting.
Some studies suggest that areas that of avid FDG uptake on PET images before treatment are also the regions most likely to have intense metabolic activity after treatment, according to Dr. Nitin Ohri, a radiation oncology resident at Thomas Jefferson University Hospital.
“Investigators are looking to PET imaging to find ways to predict if any part of the tumor would benefit from a higher radiation dose,” Ohri said. “I wanted to see if residual activity on a scan after treatment correlates with the activity pattern on a scan done before treatment.”
PET scans of 43 patients, of which 15 showed significant activity on the scans both before and after treatment, were examined. Ohri set up a coordinate system that divided tumors into nine regions, or 17 regions for larger tumors. Metabolic FDG activity in the regions both before and after treatment was then compared.
Ohri found the regions of intense FDG uptake for some patients didn’t change after treatment. However, some patients showed activity in completely different regions before and after treatment.
“It’s not sufficient to increase the dose to areas that are especially active on PET imaging before treatment and expect that to improve the control rate,” Ohri said in a release. “It may be more appropriate to do a scan halfway through treatment and plan additional radiation dose around that.”
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.